posted
Press Release Source: XTend Medical Corporation
XTend Medical (XMDC) Signs Exclusive Distribution Agreement With Diabetes Detection, Inc., a Silicon Valley Company Friday September 28, 12:12 pm ET
XTend Medical to Be First to Market Global Diabetes Technology to Millions of Physicians
SUN VALLEY, CA--(MARKET WIRE)--Sep 28, 2007 -- XTend Medical Corporation (Other OTC:XMDC.PK - News) announced the company has signed an exclusive distribution agreement with Diabetes Detection, Inc. of Palo Alto, CA, manufacturer of medical testing devices. ADVERTISEMENT
Under the terms of the agreement, XTend will sell and distribute all medical device products developed by DDI for use in the early detection of diabetic neuropathy. Neuropathy detection is used to determine the extent to which diabetic patients lose feeling in their outer extremities. DDI's current medical testing device was developed in a pager unit wherein physicians have a mobile medical device that can check the vibration threshold of the patient, thereby determining their neuropathic loss. This can help the physician in determining the proper course of treatment to minimize any further damage to the patient's extremities and lower patient costs significantly.
"We're extremely pleased to finalize this agreement with DDI. Our company now has an additional medical device to market and sell to major healthcare companies so they can diagnose neuropathy levels in patients and assist in preventing further damage to the patient, while saving the managed care companies additional costs of patient care. With the global market of diabetic neuropathy increasing, the potential sales of this unit alone in the U.S. could well exceed $150 million over the next 3-4 years," stated Mr. Paul D. Lisenby, Chairman and CEO of XTend Medical.
This press release contains or may contain forward-looking statements such as statements regarding the Company's growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements, or for prospective events that may have a retroactive effect.
Contact: Company Contact: FutureTechIR for BioPharmetics Investor Relations (817) 812-2105
-------------------------------------------------------------------------------- Source: XTend Medical Corporation
IP: Logged |
posted
FYI- XMDC was SMMW- an overwhelmingly diluted POS. They recently had a 8334:1 reverse split.
Prior to the r/s, the company had an a/s of 80 billion. That was reported in 2/06. Since the company is incorporated in Delaware and the T/A is gagged, I don't have a current count, but you can bet your britches it is well over that.
I would stay away from this POS, but good luck and god help those who decide to buy into this.
IP: Logged |
posted
So I'm guessing..Saturdays and Sundays the stock market *is* not active?...Yeah I'm still new to this thing. What sites do you go to for research?
IP: Logged |
posted
Thanks...A LOT of excellent info Tex...I will be up all night..lol...and I usually go to moneycentral for research and news. What do you think of these guys for up-to-date news?
posted
XTend Medical (XDMC) Closes on 25% Acquisition of Medical Cost Management, Inc. (MCM) Thursday October 11, 9:30 am ET MCM to Help Secure Several Large Managed Health Care Contracts
SUN VALLEY, Calif., Oct. 11 /PRNewswire-FirstCall/ -- XTend Medical Corporation (Pink Sheets: XMDC - News) announced the company has finalized its due diligence and closed the letter of intent on Medical Cost Management, Inc and has acquired a twenty-five percent stake in the company. ADVERTISEMENT
"After completing our extensive due diligence on Medical Cost Management, Inc, we're proud to announce we've acquired a twenty-five percent stake in the company. We felt that it was important to secure a portion of MCM in order for XTend to have a dedicated and focused group of sales and marketing professionals as we work on gaining contracts with managed care companies which happens to be MCM's expertise in the healthcare field. We've also negotiated a first right of refusal to purchase the remaining 75% of the company over the next 2 years through a combination of cash and/or cash and stock," stated Mr. Paul D. Lisenby, Chairman and CEO of XTend Medical Corporation. Mr. Lisenby adds, "This acquisition was done through the issuance of 2,500,000 shares of common stock that came from the original issuance of founder shares in XTend Medical. This will have no effect on the current outstanding shares within the company. XTend will continue to seek out additional acquisition and alliance opportunities that will bring considerable value to the company in order for us to grow and prosper in the healthcare arena."
Medical Cost Management issued the following statement:
"Now that we've closed this deal with XTend, our company will have a much stronger position in securing contracts with our managed care clients. The support we will receive from XTend will assist us in our current negotiations with the managed care companies we currently are in negotiations with. We're excited to be a shareholder in XTend and will work closely with Mr. Lisenby to reach his projections for 2008 and beyond," stated Mr. Jose Santoro, CEO of MCM.
About MCM: Medical Cost Management currently works with several large Managed Health Care companies in the U.S. as well as other regional and local health care insurers throughout the U.S., Puerto Rico, and Canada.
About XTend Medical: XTend Medical Corporation markets and sells healthcare and wellness products to hospitals, managed care companies, nursing homes, physician groups and individual patients. Through their alliances, XTend offers pharmacy services, diabetic supplies, and telemedicine products that increase patient care yet reduce costs associated with servicing those patients.
Safe Harbor
This press release contains or may contain forward-looking statements such as statements regarding the Company's growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements, or for prospective events that may have a retroactive effect.
Contact: Company Contact: FutureTechIR for XTend Medical Corporation Investor Relations (817) 812-2105
IP: Logged |
posted
WallSt.net Updates Investment Community Through All-New Interview With XTend Medical
NEW YORK, Oct 16, 2007 /PRNewswire via COMTEX/ -- On October 10, Paul D. Lisenby, CEO of XTend Medical Corporation (Pink Sheets: XMDC) updated the investment community in an all-new interview with www.wallst.net. Topics covered in the interview include an overview of the company and its growth strategy, recent press releases, market opportunity, and upcoming milestones for which investors should watch. To hear the interview in its entirety, visit http://www.wallst.net and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange at the top of the "Interviews" section of the site or by entering the company's ticker symbol in the Search Archive window.
About XTend Medical:
XTend Medical Corporation markets and sells healthcare and wellness products to hospitals, managed care companies, nursing homes, physician groups and individual patients. Through their alliances, XTend offers pharmacy services, diabetic supplies, and telemedicine products that increase patient care yet reduce costs associated with servicing those patients.
About WallSt.net:
www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The Web site is a leading provider of timely business news, executive interviews, multimedia content and research tools. Financial Media Group, Inc. also owns http://www.mywallst.net, a financial social network for investors, and Financial Filings Corp., a provider of compliance solutions to publicly traded companies. Additionally, WallStreet Direct, Inc. owns and operates WallStRadio, a business and finance podcast Web site. Financial Filings Corp. has received one million two hundred fifty thousand restricted shares of XMDC from XTend Medical Corporation for media and advertising services. For a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp.
posted
(XDMC) Adds New Bluetooth(R) Telemedicine Products From A&D Medical Thursday October 18, 5:00 am ET Bluetooth(R) Wireless Blood Pressure Cuff and Weight Scale Added to Our Telemedicine Product Line
SUN VALLEY, Calif., Oct. 18 /PRNewswire-FirstCall/ -- XTend Medical Corporation (Pink Sheets: XMDC - News) announced the company has added two new Bluetooth® enabled telemedicine products to their line of disease management solutions for sales to managed care, hospitals, long term care facilities, and physician groups. ADVERTISEMENT
"The addition of A & D's Bluetooth® enabled Blood Pressure Cuff and Weight Scale will give us the opportunity to package our offerings to the various healthcare organizations in order to effectively monitor their patients with the most up to date technology in the healthcare arena. As we target the larger managed health care companies, this technology allows us to not only target diabetic patients, our main focus, but also gives us the ability to present to managed care companies a cutting-edge solution for chronic conditions in heart and kidney patients. This increases our opportunity to generate significant sales and imbeds us further with gaining additional long term contracts. XTend Medical, through R&D expenditures and exclusive agreements, continues to ensure our position as a leading provider of telemedicine products and services for years to come," stated Mr. Paul D. Lisenby, Chairman and CEO of XTend Medical.
About A & D:
A&D Medical is a division of A&D, an ISO 9002-registered company with operations in Asia, Europe, Australia, Russia, and North and South America. Since 1977, A&D Medical has manufactured and distributed a full line of advanced electronic blood pressure monitoring equipment and health care products for home and professional use. The company has established itself as a leader in home health monitoring technology through the development and introduction of a variety of unique products. A&D's LifeSource® blood pressure monitor line has garnered numerous industry awards. Recent product introductions include: the LifeSource® digital thermometers, personal scales, stethoscopes, and Ambulatory Blood Pressure Monitors.
XTend Medical Corporation markets and sells healthcare and wellness products to hospitals, managed care companies, nursing homes, physician groups and individual patients. Through their alliances, XTend offers pharmacy services, diabetic supplies, and telemedicine products that increase patient care yet reduce costs associated with servicing those patients.
Safe Harbor: This press release contains or may contain forward-looking statements such as statements regarding the Company's growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements, or for prospective events that may have a retroactive effect.
Company Contact: FutureTechIR for XTend Medical Corporation
Investor Relations (817) 812-2105
-------------------------------------------------------------------------------- Source: XTend Medical Corporation
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
